CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Coherus Oncology Inc (CHRS) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has promising analyst coverage and financial growth trends, the recent sharp price decline, lack of significant trading signals, and negative market sentiment suggest holding off on immediate investment until the stock stabilizes.
The technical indicators show mixed signals. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 41.139, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below key support levels (S1: 1.981, current price: 1.665), which signals potential further downside.
Analysts have initiated coverage with an Outperform rating and a $10 price target, citing promising clinical developments.
Strong YoY financial growth in revenue (+91.19%) and gross margin (+23.55%) in Q3 2025.
Recent public offering at $1.75 per share has diluted equity and caused a sharp post-market price drop (-17.12%).
Net income and EPS remain negative despite YoY improvement.
No significant hedge fund or insider trading activity, and no recent congress trading data.
In Q3 2025, revenue increased by 91.19% YoY to $11.57M, and gross margin rose to 67.84%. However, the company remains unprofitable, with a net loss of $35.53M and an EPS of -0.31, despite significant YoY improvement.
Oppenheimer initiated coverage with an Outperform rating and a $10 price target, citing upcoming clinical readouts and high-potential early-stage opportunities.
